CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-29 | Klein Lawrence Otto Director | Grant or award · Stock Option (Right to Buy) | +23,017 | 23,017 | ||
| 2025-04-29 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +23,017 | 23,017 | ||
| 2025-04-29 | DOBMEIER ERIC Director | Grant or award · Stock Option (Right to Buy) | +23,017 | 23,017 | ||
| 2025-04-28 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other acquisition | +1,062,326 | 1,287,858 | ||
| 2024-08-01 | Dake Benjamin T SEE REMARKS | Option exercise | +1,507 | $1.74 | $3K | 14,252 |
| 2024-08-01 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) | −1,507 | 0 | ||
| 2024-07-31 | Dake Benjamin T SEE REMARKS | Option exercise | +11,454 | $1.74 | $20K | 12,745 |
| 2024-07-31 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) | −906 | 0 | ||
| 2024-07-31 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) | −10,548 | 1,507 | ||
| 2024-06-17 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +928,110 | $1.67 | $1.5M | 7,893,678 |
| 2024-06-14 | Eldridge George A SEE REMARKS | Option exercise 10b5-1 | +15,000 | $2.14 | $32K | 20,022 |
| 2024-06-14 | Eldridge George A SEE REMARKS | Sale 10b5-1 | −15,000 | $25.03 | $375K | 5,022 |
| 2024-06-14 | Eldridge George A SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 28,763 | ||
| 2024-06-14 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Option exercise 10b5-1 | +10,600 | $14.59 | $155K | 10,600 |
| 2024-06-14 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale 10b5-1 | −10,600 | $25.00 | $265K | 0 |
| 2024-06-14 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,600 | 68,800 | ||
| 2024-06-13 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +6,000 | $2.14 | $13K | 11,602 |
| 2024-06-13 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −6,000 | $24.50 | $147K | 5,602 |
| 2024-06-13 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 83,510 | ||
| 2024-06-05 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 |
Page 2 of 16 · 315 trades